Literature DB >> 10961491

Guidelines for the treatment of adults with severe head trauma (part II). Criteria for medical treatment.

F Procaccio1, N Stocchetti, G Citerio, M Berardino, L Beretta, F Della Corte, D D'Avella, G L Brambilla, R Delfini, F Servadei, G Tomei.   

Abstract

Since 1995 a Group of Italian Neurointensivists and Neurosurgeons belonging to the Italian Societies of Neurosurgery (SINch) and Anesthesia & Intensive Care (SIAARTI) has produced some recommendations for treatment of adults with severe head trauma. They have been published in 3 parts: Part I (Initial assessment, Evaluation and pre-hospital treatment, Criteria for hospital admission, Systemic and cerebral monitoring), Part II (Medical treatment) and Part III (Surgical treatment criteria). These recommendations reflect a multidisciplinary consent and are mostly based on expert opinion. The main aim is to provide a practical reference for all those dealing with severe head injuries from first-aid to intensive care units, setting out the minimal goals of management to be reached throughout the Country. These recommendations need a continuous critical review and updating. Medical treatment is aimed at preventing or minimizing secondary brain damage following acute brain injury, provided that surgical masses have been promptly identified and removed. In order to assure cerebral perfusion, systemic hemodynamics and respiratory exchanges should be normal. Volemia is crucial, and mean arterial pressure should remain above 90 mmHg. Good general intensive care, including gastroprotection, water-electrolyte balance, infection control, nutrition and physiotherapy, is assumed as the basis for brain-oriented therapy. Intracranial hypertension requires an approach based on various steps. First, factors that can directly rise intracranial pressure (ICP) such as venous outflow obstruction, fever, pain etc. should be checked and corrected. Second, Mannitol, CSF withdrawal, sedation and moderate hyperventilation should be applied. This can be done by targeting specific problems with specific treatment (which is possible when the cause of ICP rise is known) or in a step-wise approach, by using less aggressive interventions before than more aggressive ones, with a higher risk of complications. Third, extreme treatment, such as barbiturates, should be reserved to cases with refractory intracranial hypertension. The main goal of ICP treatment is not simply ICP reduction, but the maintenance of adequate cerebral perfusion pressure.

Entities:  

Mesh:

Year:  2000        PMID: 10961491

Source DB:  PubMed          Journal:  J Neurosurg Sci        ISSN: 0390-5616            Impact factor:   2.279


  4 in total

1.  The key role of the radiologist in the management of polytrauma patients: indications for MDCT imaging in emergency radiology.

Authors:  Gerd Schueller; Mariano Scaglione; Ulrich Linsenmaier; Claudia Schueller-Weidekamm; Chiara Andreoli; Marina De Vargas Macciucca; Gianfranco Gualdi
Journal:  Radiol Med       Date:  2015-01-30       Impact factor: 3.469

2.  Medical management of compromised brain oxygen in patients with severe traumatic brain injury.

Authors:  Leif-Erik Bohman; Gregory G Heuer; Lukascz Macyszyn; Eileen Maloney-Wilensky; Suzanne Frangos; Peter D Le Roux; Andrew Kofke; Joshua M Levine; Michael F Stiefel
Journal:  Neurocrit Care       Date:  2011-06       Impact factor: 3.210

3.  Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients - a randomized clinical trial [ISRCTN62699180].

Authors:  Lilit Harutjunyan; Carsten Holz; Andreas Rieger; Matthias Menzel; Stefan Grond; Jens Soukup
Journal:  Crit Care       Date:  2005-08-09       Impact factor: 9.097

Review 4.  The Significance of Intracranial Pressure Monitoring for Reducing Mortality in Patients with Traumatic Brain Injury: A Systematic Review and Meta-Analysis.

Authors:  Nianchen Han; Fan Yang; Xianghe Zhang
Journal:  Comput Math Methods Med       Date:  2022-10-08       Impact factor: 2.809

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.